CN105796560A - 环丙沙星的药物组合物及其在生物医药中的应用 - Google Patents
环丙沙星的药物组合物及其在生物医药中的应用 Download PDFInfo
- Publication number
- CN105796560A CN105796560A CN201610260394.3A CN201610260394A CN105796560A CN 105796560 A CN105796560 A CN 105796560A CN 201610260394 A CN201610260394 A CN 201610260394A CN 105796560 A CN105796560 A CN 105796560A
- Authority
- CN
- China
- Prior art keywords
- ciprofloxacin
- compound
- extract
- preparation
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 title claims abstract description 74
- 229960003405 ciprofloxacin Drugs 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 43
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 19
- 238000010828 elution Methods 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000003208 petroleum Substances 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- -1 electuary Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000012259 ether extract Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 238000010829 isocratic elution Methods 0.000 claims description 3
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002027 dichloromethane extract Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 238000011017 operating method Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 6
- 229930014626 natural product Natural products 0.000 abstract description 6
- 238000011552 rat model Methods 0.000 abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 208000031229 Cardiomyopathies Diseases 0.000 abstract description 3
- 210000004165 myocardium Anatomy 0.000 abstract description 3
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 210000005240 left ventricle Anatomy 0.000 description 13
- 102000008186 Collagen Human genes 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 241000700159 Rattus Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 8
- 230000002861 ventricular Effects 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000001427 coherent effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
- 229960002591 hydroxyproline Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101000874172 Rattus norvegicus Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HNVJWWBKFFDQAA-NRKPLWJESA-N [(7r,8r,8ar)-7-hydroxy-7-methyl-6-oxo-3-[(e)-prop-1-enyl]-8,8a-dihydro-1h-isochromen-8-yl] 2,4-dihydroxy-6-methylbenzoate Chemical compound O([C@H]1[C@@](C)(O)C(=O)C=C2C=C(OC[C@@H]21)/C=C/C)C(=O)C1=C(C)C=C(O)C=C1O HNVJWWBKFFDQAA-NRKPLWJESA-N 0.000 description 1
- OBOXTJCIIVUZEN-UHFFFAOYSA-N [C].[O] Chemical compound [C].[O] OBOXTJCIIVUZEN-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229930190137 cohaerin Natural products 0.000 description 1
- 230000009091 contractile dysfunction Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000002072 distortionless enhancement with polarization transfer spectrum Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000009432 framing Methods 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000686 lactone group Chemical group 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000001896 rotating frame Overhauser effect spectroscopy Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了环丙沙星的药物组合物及其在生物医药中的应用,本发明提供的环丙沙星的药物组合物中含有环丙沙星和一种从川芎的干燥根茎中分离得到的结构新颖的天然产物化合物(Ⅰ),环丙沙星、化合物(Ⅰ)对2型糖尿病心肌病大鼠模型的心肌具有保护作用,环丙沙星与化合物(Ⅰ)联合使用后,保护效果更好,可以开发成治疗糖尿病心肌病的药物,与现有技术相比具有突出的实质性特点和显著的进步。
Description
技术领域
本发明属于生物医药领域,涉及环丙沙星的新用途,具体涉及环丙沙星的药物组合物及其在生物医药中的应用。
背景技术
环丙沙星为合成的第三代喹诺酮类抗菌药物,具广谱抗菌活性,杀菌效果好,几乎对所有细菌的抗菌活性均较诺氟沙星及依诺沙星强2~4倍,对肠杆菌、绿脓杆菌、流感嗜血杆菌、淋球菌、链球菌、军团菌、金黄色葡萄球菌具有抗菌作用。
糖尿病心肌病(diabeticcardiomyopathy,DC)是糖尿病心脏病(diabeticheartdisease,DHD)的一类特异性病变,与糖尿病患者的心力衰竭高发生率和高死亡率密切相关。DC发病隐匿,早期临床症状不明显,与其它糖尿病并发症相比,研究相对滞后,相关治疗药物研究受到关注。目前用于DC研究的模型动物主要采取单纯高热量饮食诱导、单纯化学因素诱导、高热量饮食负荷化学因素诱导以及转基因动物。其中高热量饮食负荷化学因素诱导的模型动物所出现的糖、脂代谢紊乱和心脏病变与临床患者的发病规律更相近。针对患者临床出现的糖脂代谢紊乱、心肌纤维化、微小血管病变、胰岛素抵抗等特征,当前治疗手段包括降糖制剂(如双胍类)、血管紧张素转化酶抑制剂、钙离子拮抗剂等,另外调脂、抗氧化和胰岛素增敏制剂(噻唑烷二酮类)也有广泛的应用,所使用药物多针对DC发病的某一环节。
迄今为止,尚未见环丙沙星及其药物组合物与糖尿病心肌病的相关性报道。
发明内容
本发明的目的在于提供一种环丙沙星的药物组合物,该药物组合物中含有环丙沙星和一种结构新颖的天然产物,环丙沙星和该天然产物可以协同治疗糖尿病心肌病。
本发明的上述目的是通过下面的技术方案得以实现的:
一种具有下述结构式的化合物(Ⅰ),
一种环丙沙星的药物组合物,包括环丙沙星、如权利要求1所述的化合物(Ⅰ)和药学上可以接受的载体,制备成需要的剂型。
进一步地,药学上可以接受的载体包括稀释剂、赋形剂、填充剂、粘合剂、湿润剂、崩解剂、吸收促进剂、表面活性剂、吸附载体或润滑剂。
进一步地,所述剂型包括片剂、胶囊剂、口服液、口含剂、颗粒剂、冲剂、丸剂、散剂、膏剂、丹剂、混悬剂、粉剂、溶液剂、注射剂、栓剂、喷雾剂、滴剂或贴剂。
上述化合物(Ⅰ)的制备方法,包含以下操作步骤:(a)将川芎的干燥根茎粉碎,用60~70%乙醇热回流提取,合并提取液,浓缩至无醇味,依次用石油醚、乙酸乙酯和水饱和的正丁醇萃取,分别得到石油醚萃取物、乙酸乙酯萃取物和正丁醇萃取物;(b)步骤(a)中正丁醇萃取物用大孔树脂除杂,先用10%乙醇洗脱12个柱体积,再用70%乙醇洗脱15个柱体积,收集70%洗脱液,减压浓缩得70%乙醇洗脱浓缩物;(c)步骤(b)中70%乙醇洗脱浓缩物用正相硅胶分离,依次用体积比为50:1、25:1、15:1和5:1的二氯甲烷-甲醇梯度洗脱得到4个组分;(d)步骤(c)中组分4用正相硅胶进一步分离,依次用体积比为10:1、5:1和2:1的二氯甲烷-甲醇梯度洗脱得到3个组分;(e)步骤(d)中组分2用十八烷基硅烷键合的反相硅胶分离,用体积百分浓度为70%的甲醇水溶液等度洗脱,收集7~13个柱体积洗脱液,洗脱液减压浓缩得到化合物(Ⅰ)。
进一步地,化合物(Ⅰ)的制备方法中,步骤(a)用65%乙醇热回流提取,合并提取液。
进一步地,化合物(Ⅰ)的制备方法中,所述大孔树脂为AB-8型大孔吸附树脂。
进一步地,化合物(Ⅰ)的制备方法中,步骤(a)中用二氯甲烷代替乙酸乙酯进行萃取,得到二氯甲烷萃取物。
上述化合物(Ⅰ)在制备治疗糖尿病心肌病的药物中的应用。
上述环丙沙星的药物组合物在制备治疗糖尿病心肌病的药物中的应用。
本发明的优点:
本发明提供的环丙沙星的药物组合物中含有环丙沙星和一种从川芎的干燥根茎中分离得到的结构新颖的天然产物,环丙沙星和该天然产物单独作用时,具有治疗糖尿病心肌病作用;二者联合作用时,治疗糖尿病心肌病效果进一步提高,可以开发成治疗糖尿病心肌病的药物。
具体实施方式
下面结合实施例进一步说明本发明的实质性内容,但并不以此限定本发明保护范围。
实施例1:化合物(Ⅰ)分离制备及结构确证
试剂来源:乙醇、石油醚、乙酸乙酯、正丁醇、二氯甲烷为分析纯,购自上海凌峰化学试剂有限公司,甲醇,分析纯,购自江苏汉邦化学试剂有限公司。
分离方法:(a)将川芎的干燥根茎(2kg)粉碎,用65%乙醇热回流提取(20L×3次),合并提取液,浓缩至无醇味(4L),依次用石油醚(4L×3次)、乙酸乙酯(4L×3次)和水饱和的正丁醇(4L×3次)萃取,分别得到石油醚萃取物、乙酸乙酯萃取物和正丁醇萃取物;(b)步骤(a)中正丁醇萃取物用AB-8型大孔树脂除杂,先用10%乙醇洗脱12个柱体积,再用70%乙醇洗脱15个柱体积,收集70%洗脱液,减压浓缩得70%乙醇洗脱浓缩物;(c)步骤(b)中70%乙醇洗脱浓缩物用正相硅胶分离,依次用体积比为50:1(8个柱体积)、25:1(8个柱体积)、15:1(8个柱体积)和5:1(10个柱体积)的二氯甲烷-甲醇梯度洗脱得到4个组分;(d)步骤(c)中组分4用正相硅胶进一步分离,依次用体积比为10:1(8个柱体积)、5:1(10个柱体积)和2:1(5个柱体积)的二氯甲烷-甲醇梯度洗脱得到3个组分;(e)步骤(d)中组分2用十八烷基硅烷键合的反相硅胶分离,用体积百分浓度为70%的甲醇水溶液等度洗脱,收集7~13个柱体积洗脱液,洗脱液减压浓缩得到化合物(Ⅰ)(385mg,HPLC归一化纯度大于98%)。
结构确证:HR-ESI-MS显示[M+H]+为m/z483.2343,结合核磁特征可得分子式为C28H34O7,不饱和度为12。核磁共振氢谱数据δH(ppm,CD3OD,500MHz):H-1(6.81,s),H-4(6.05,s),H-5(5.38,s),H-8(3.79,m),H-9(1.36,m),H-10(2.91,d,J=12.4Hz),H-11(2.08,m),H-12(2.83,dd,J=11.9,5.3Hz),H-12(3.11,dd,J=11.9,7.7Hz),H-14(2.69,dd,J=12.4,13.3Hz),H-14(2.92,dd,J=12.4,3.6Hz),H-16(1.02,d,J=6.5Hz),H-18(4.07,dd,J=12.7Hz),H-20(3.24,dqd,J=13.2,7.4,6.5Hz),H-21(1.34,m),H-21(1.77,m),H-22(1.20,m),H-22(1.26,m),H-23(1.24,m,2H),H-24(1.24,m,2H),H-25(1.25,m,2H),H-26(0.88,t,J=7.2Hz),H-27(1.21,d,J=7.2Hz);核磁共振碳谱数据δC(ppm,CD3OD,125MHz):143.3(CH,1-C),156.6(C,3-C),110.8(CH,4-C),144.2(C,4a-C),107.3(CH,5-C),190.8(C,6-C),82.4(C,7-C),43.5(CH,8-C),116.3(C,8a-C),19.2(CH3,9-C),62.1(CH,10-C),16.1(CH,11-C),48.6(CH2,12-C),193.5(C,13-C),59.8(CH2,14-C),207.1(C,15-C),20.3(CH3,16-C),169.3(C,17-C),51.1(CH,18-C),206.3(C,19-C),46.3(CH,20-C),32.7(CH2,21-C),27.6(CH2,22-C),29.0(CH2,23-C),31.3(CH2,24-C),22.2(CH2,25-C),14.2(CH3,26-C),16.6(CH3,27-C)。红外波谱中的1710cm-1吸收带与UV谱中的224nm吸收带表明该化合物含有α,β-不饱和羰基结构。13C-NMR、DEPT和HSQC谱中显示有28个碳信号,包括四个甲基,七个亚甲基,八个次甲基(三个烯烃碳),以及九个季碳(一个连氧碳,五个羰基碳和三个烯烃碳),以上功能结构再结合不饱和数表明该化合物为四环结构。核磁数据表明该化合物含有一个α,β-不饱和羰基结构[δH5.38(1H,s,H-5);δC144.2(C-4a),107.3(C-5),190.8(C-6)],一个五元内酯环[δH3.79(1H,m,H-8),4.07(1H,dd,J=12.7Hz,H-18);δC82.4(C-7),43.5(C-8),169.3(C-17),51.1(C-18)],一个2-甲基辛酰基片段[δH3.24(1H,dqd,J=13.2,7.4,6.5Hz,H-20),1.77(1H,m,H-21),1.34(1H,m,H-21),1.26(1H,m,H-22),1.20(1H,m,H-22),1.24(2H,m,H-23),1.24(2H,m,H-24),1.25(2H,m,H-25),0.88(3H,t,J=7.2Hz,H-26),1.21(3H,d,J=7.2Hz,H-27);δC206.3(C-19),46.3(C-20),32.7(C-21),27.6(C-22),29.0(C-23),31.3(C-24),22.2(C-25),14.2(C-26),16.6(C-27)]。由1H-1HCOSY谱中显示的H3-27/H-20/H2-21/H2-22/H2-23/H2-24/H2-25/H3-26相关信号与HMBC谱中显示的H-18与C-8和C-19,H-20与C-19相关信号以及相关碳化学位移可以确认2-甲基辛酰基存在。另1H-1HCOSY谱中存在H-10/H-11/H2-12相关信号结合HMBC谱中显示的H-1与C-4a、C-8a和C-8,H-4与C-3、C-4a和C-8a,H-5与C-4、C-4a和C-6,H-8与C-7、C-8a和C-18,H-10与C-3、C-11、C-15和C-16,H2-12与C-11、C-13、C-14和C-16,H2-14与C-12、C-13和C-15,H-18与C-8和C-17相关信号,可以推测azaphilone骨架结构存在。因此,根据上述结构片段构建化合物可以确认为Cohaerin衍生物。综合氢谱、碳谱、HMBC谱和ROESY谱,以及文献关于相关类型核磁数据,可基本确定该化合物如下所示,立体构型进一步通过ECD试验确定,理论值与实验值基本一致。
该化合物化学式及碳原子编号如下:
实施例2:药理作用
1、材料与方法
1.1动物
SPF级♂Wistar大鼠,体质量(180±20)g,北京维通利华实验动物技术有限公司提供。于室温22℃~25℃,相对湿度65%,12h明暗交替环境中适应3d后进入实验。
1.2试剂与样品
环丙沙星购自中国食品药品检定研究院。化合物(Ⅰ)自制,制备方法见实施例1。高糖高脂饲料(20%蔗糖、10%猪油、2.5%胆固醇、1%胆盐和66.5%基础饲料),北京科澳协力饲料有限公司提供;链脲佐菌素(streptozotocin,STZ),Sigma公司提供;柠檬酸,北京化工厂提供;柠檬酸钠,北京化工厂提供。ELISA测试盒由加拿大GroudworkBiotechnologyDiagnosticateLtd.提供。
1.3仪器
OHAUS天平:TP200型,OHAUS,美国;离心机:HERAEUSINSTRUMENTS,KendrolaboratoryProducts,德国;紫外分光光度计:AGILENT8453,AgilentTechologies,德国;BIOPACSYSTEMMP150,BiopacSystemInc.,美国;全自动多功能酶标仪:MULTISKANMK3,Thermo产品,美国;电热恒温培养箱:DH4000A,天津泰斯特产品。
1.4大鼠分组及2型糖尿病心肌病(DC)大鼠模型制备
90只大鼠按体重随机取15只作为正常对照组(Control),实验过程始终给予普通饲料喂养。其余75只喂饲高糖高脂饲料,6周后,按照30mg·kg-1剂量一次性腹腔注射(i.p.)STZ(以柠檬酸-柠檬酸钠缓冲液稀释,pH4.5,4℃配制,随配随用),Control大鼠ip同体积柠檬酸-柠檬酸钠缓冲液。72h后,用ONETOUCH测定血糖,以禁食12h血糖≥7.8mmol·L-1认为是糖尿病模型成功(成功率为80%)。选取动物60只,按血糖水平随机分为4组,分别为模型对照组(糖尿病心肌病模型组)、环丙沙星组(30mg·kg-1)、化合物(Ⅰ)组(30mg·kg-1)、环丙沙星与化合物(Ⅰ)组合物组【15mg·kg-1环丙沙星+15mg·kg-1化合物(Ⅰ)】。每组15只,于注射STZ72h后,每天按相应剂量灌胃给药,药物均以0.5%羧甲基纤维素钠(CMC-Na)混悬,给药时间为8:00~10:00am。Control组和DC模型组给相应体积0.5%CMC-Na溶液,共给药6周。给药期间,Control组喂饲普通饲料,其余各组同前给高糖高脂饲料,自由进水,直至实验结束(共12周)。
1.5左心室形态学观察
沿大鼠心脏左心室赤道面横切,取适量心肌组织,加10倍量福尔马林固定,石蜡包埋,切片(厚度4μm),常规HE染色。显微镜下观察左心室形态,用Image-ProPlus5.0专业图像分析软件测定左心室前壁厚度(LVWT)和室间隔厚度(IST)。每组3~4只动物,每只动物观察2张切片,取平均值。
1.6左心室胶原含量测定
取约0.1g左心室组织,按试剂盒说明书要求测定样品中羟脯氨酸含量。依据胶原中羟脯氨酸含量13.4%比例,胶原(collagen)含量以羟脯氨酸×7.46计算,结果以mg·g-1组织表示。
1.7统计学方法
实验数据用均数±标准差(x±s)表示,应用SPSS18.0版统计软件进行单因素方差分析和t检验,以P<0.05为差异有统计学意义。
2、实验结果
2.1对2型DC模型大鼠心室壁厚度的影响
模型对照组大鼠心室间隔厚度(IST)和左心室前壁厚度(LVWT)增加,高于空白对照组(P<0.05),说明造模成功。与模型对照组比较,环丙沙星组、化合物(Ⅰ)组大鼠实验后心室间隔厚度(IST)和左心室前壁厚度(LVWT)降低,差异均有统计学意义(P<0.05);与模型对照组比较,环丙沙星与化合物(Ⅰ)组合物组心室间隔厚度(IST)和左心室前壁厚度(LVWT)明显降低(P<0.01)。结果见表1。
2.2对2型DC模型大鼠左心室胶原含量的影响
与正常对照组比较,模型对照组大鼠左心室胶原含量明显增加(P<0.05)。与模型对照组比较,环丙沙星与化合物(Ⅰ)组合物组大鼠左心室胶原含量明显降低(P<0.01);与模型对照组比较,环丙沙星组、化合物(Ⅰ)组大鼠左心室胶原含量降低(P<0.05)。动物心肌组织胶原含量得到改善。结果见表1。
表1对2型DC模型大鼠心室壁厚度和左心室胶原含量的影响
组别 | IST/mm | LVWT/mm | 胶原含量/mg·g-1 |
正常对照组 | 1.04±0.11 | 2.30±0.42 | 2.7±0.5 |
模型对照组 | 1.86±0.14 | 3.06±1.11 | 3.3±0.6 |
环丙沙星组 | 1.48±0.11 | 2.64±0.68 | 2.7±0.4 |
化合物(Ⅰ)组 | 1.46±0.23 | 2.58±0.22 | 2.6±0.7 |
环丙沙星与化合物(Ⅰ)组合物组 | 1.18±0.02 | 2.34±0.68 | 2.2±0.4 |
糖尿病心肌病(DC)是由于心肌细胞原发性损伤引起广泛的结构异常最终引起左心室肥厚、舒张期和(或)收缩期功能障碍的一种疾病状态。DC发病早期以出现心肌纤维化异常以及左心室肥厚发生为特点,表现为心肌细胞结构改变,左心室容积、室壁厚度和紧张性以及左心室重量增加;随着疾病发展TG堆积和Ca2+转运缺陷严重,成纤维细胞增殖以替代死亡的心肌细胞,并由转化生长因子-β1(TGF-β1)介导心肌细胞的纤维化,导致左心室舒张功能下降,并逐渐转变为以扩张型心脏重塑为特点的收缩功能障碍,进一步可能发展成为缺血性心脏病和心衰。
上述结果表明,环丙沙星、化合物(Ⅰ)对2型糖尿病心肌病大鼠模型的心肌具有保护作用,环丙沙星与化合物(Ⅰ)联合使用后,保护效果更好,可以开发成治疗糖尿病心肌病的药物,与现有技术相比,具有突出的实质性特点和显著的进步。
上述实施例的作用在于说明本发明的实质性内容,但并不以此限定本发明的保护范围。本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的实质和保护范围。
Claims (10)
1.一种具有下述结构式的化合物(Ⅰ),
2.一种环丙沙星的药物组合物,其特征在于:包括环丙沙星、如权利要求1所述的化合物(Ⅰ)和药学上可以接受的载体,制备成需要的剂型。
3.根据权利要求2所述的环丙沙星的药物组合物,其特征在于:药学上可以接受的载体包括稀释剂、赋形剂、填充剂、粘合剂、湿润剂、崩解剂、吸收促进剂、表面活性剂、吸附载体或润滑剂。
4.根据权利要求2所述的环丙沙星的药物组合物,其特征在于:所述剂型包括片剂、胶囊剂、口服液、口含剂、颗粒剂、冲剂、丸剂、散剂、膏剂、丹剂、混悬剂、粉剂、溶液剂、注射剂、栓剂、喷雾剂、滴剂或贴剂。
5.权利要求1所述的化合物(Ⅰ)的制备方法,其特征在于,包含以下操作步骤:(a)将川芎的干燥根茎粉碎,用60~70%乙醇热回流提取,合并提取液,浓缩至无醇味,依次用石油醚、乙酸乙酯和水饱和的正丁醇萃取,分别得到石油醚萃取物、乙酸乙酯萃取物和正丁醇萃取物;(b)步骤(a)中正丁醇萃取物用大孔树脂除杂,先用10%乙醇洗脱12个柱体积,再用70%乙醇洗脱15个柱体积,收集70%洗脱液,减压浓缩得70%乙醇洗脱浓缩物;(c)步骤(b)中70%乙醇洗脱浓缩物用正相硅胶分离,依次用体积比为50:1、25:1、15:1和5:1的二氯甲烷-甲醇梯度洗脱得到4个组分;(d)步骤(c)中组分4用正相硅胶进一步分离,依次用体积比为10:1、5:1和2:1的二氯甲烷-甲醇梯度洗脱得到3个组分;(e)步骤(d)中组分2用十八烷基硅烷键合的反相硅胶分离,用体积百分浓度为70%的甲醇水溶液等度洗脱,收集7~13个柱体积洗脱液,洗脱液减压浓缩得到化合物(Ⅰ)。
6.根据权利要求5所述的化合物(Ⅰ)的制备方法,其特征在于:步骤(a)用65%乙醇热回流提取,合并提取液。
7.根据权利要求5所述的化合物(Ⅰ)的制备方法,其特征在于:所述大孔树脂为AB-8型大孔吸附树脂。
8.根据权利要求5所述的化合物(Ⅰ)的制备方法,其特征在于:步骤(a)中用二氯甲烷代替乙酸乙酯进行萃取,得到二氯甲烷萃取物。
9.权利要求1所述的化合物(Ⅰ)在制备治疗糖尿病心肌病的药物中的应用。
10.权利要求2~4任一所述的环丙沙星的药物组合物在制备治疗糖尿病心肌病的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610260394.3A CN105796560A (zh) | 2016-04-23 | 2016-04-23 | 环丙沙星的药物组合物及其在生物医药中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610260394.3A CN105796560A (zh) | 2016-04-23 | 2016-04-23 | 环丙沙星的药物组合物及其在生物医药中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105796560A true CN105796560A (zh) | 2016-07-27 |
Family
ID=56457599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610260394.3A Pending CN105796560A (zh) | 2016-04-23 | 2016-04-23 | 环丙沙星的药物组合物及其在生物医药中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105796560A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105777516A (zh) * | 2016-04-23 | 2016-07-20 | 何淑琼 | 盐酸安非他酮的药物组合物及其在生物医药中的应用 |
CN106083800A (zh) * | 2016-06-13 | 2016-11-09 | 崔坤峰 | 氯普噻吨的药物组合物及对脑缺血再灌注损伤的保护作用 |
WO2017220044A3 (zh) * | 2016-06-23 | 2018-02-15 | 赵吉永 | 联苯苄唑的药物组合物及其保肝作用 |
-
2016
- 2016-04-23 CN CN201610260394.3A patent/CN105796560A/zh active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105777516A (zh) * | 2016-04-23 | 2016-07-20 | 何淑琼 | 盐酸安非他酮的药物组合物及其在生物医药中的应用 |
CN106083800A (zh) * | 2016-06-13 | 2016-11-09 | 崔坤峰 | 氯普噻吨的药物组合物及对脑缺血再灌注损伤的保护作用 |
WO2017220044A3 (zh) * | 2016-06-23 | 2018-02-15 | 赵吉永 | 联苯苄唑的药物组合物及其保肝作用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5363986B2 (ja) | 認知症及び軽度認識障害の治療、及び認知機能の改善に有効であるオレアナン系トリテルペンサポニン化合物 | |
CN101279964B (zh) | 愈创木烷型倍半萜、其制备方法及其医药用途 | |
WO2006034655A1 (fr) | Composition pharmaceutique a base de saponines steroidiques, son procede de preparation et son utilisation | |
CN105796560A (zh) | 环丙沙星的药物组合物及其在生物医药中的应用 | |
TWI432420B (zh) | A compound isolated from the monascus, a process for its preparation and use | |
CN105524063A (zh) | 一种新的萜类吲哚生物碱化合物及其制备方法和医药用途 | |
CN111454317B (zh) | 具有抗炎活性的人参二醇型三萜皂苷、三七叶提取物、药物组合物和化妆品组合物 | |
TW201335177A (zh) | 甾醇類衍生物及其製備方法與應用 | |
CN105837595A (zh) | 阿替洛尔的药物组合物及其在生物医药中的应用 | |
CN105777854A (zh) | 硫酸依替米星的药物组合物及其在生物医药中的应用 | |
Zanwar et al. | Flax lignan in the prevention of atherosclerotic cardiovascular diseases | |
CN106496245A (zh) | 赖诺普利的药物组合物及其在生物医药中的应用 | |
CN105693743A (zh) | 氯碘羟喹的药物组合物及其在生物医药中的应用 | |
CN106109459A (zh) | 盐酸地匹福林的药物组合物及其在生物医药中的应用 | |
Maciel et al. | Pharmacological and biochemical profiling of lead compounds from traditional remedies: the case of Croton cajucara | |
CN110204589B (zh) | 青葙子有效成分、提取方法及其在制备神经保护药物方面的应用 | |
CN105147711B (zh) | 一种连翘活性部位的制备及其在防治帕金森病中的应用 | |
CN111329866A (zh) | 一种五环三萜类化合物在制备抗偏头痛药物中的应用 | |
CN105753830A (zh) | 艾司唑仑的药物组合物及其在生物医药中的应用 | |
US10391104B2 (en) | Application of antidepressant compound in preparation of antidepressant drugs and antidepressant health-care foods | |
CN109180632A (zh) | 一种从雷公藤中分离出的新化合物及其制备方法和医药用途 | |
CN114533719B (zh) | 松香烷型二萜类化合物在制备抗炎药物中的应用 | |
TWI466674B (zh) | 臺灣梭羅木之生物活性組合物 | |
CN115429790B (zh) | 异黄酮类化合物在制备预防或治疗酒精性肝损伤或解酒保肝的药物中的用途 | |
CN114539192B (zh) | 松香烷型二萜化合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160727 |